Acrux licenses Lenzetto for Australian market for AUD5.4m
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Acrux Limited has announced the licensing of its product Lenzetto® for the Australian market, which aims to address a shortage of Menopause Hormone Therapy products in the country. The amended agreement with Gedeon Richter Plc includes milestone payments that could total a significant amount over the next two years following the product's launch. The CEO of Acrux expressed that this agreement will benefit both Australian women and the company's financial position.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Acrux
- Capital Gains Tax exemptions remain in place for Acrux
- Acrux raises $1.6 million via Share Placement
- Australian company unlocks a new era for women's health globally with an innovative delivery system for Female testosterone in women with low libido
- Acrux strategy focuses on Female Testosterone for low libido
- Acrux receives $0.55m advance on FY26 R&D Tax Incentive
Later from Acrux
- Update - Licensing Lenzetto for Australia for AUD5.4m
- Notification regarding unquoted securities - ACR
- Application for quotation of securities - ACR
- Cleansing Notice
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Acrux into a list and get an email when it puts out news.
Follow Acrux